Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA INVESTIGATION UPDATE: ADMA Biologics Investors are Notified of Securities Fraud Investigation into Auditor Resignation; Contact BFA Law if You Lost Money (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics, Inc. is currently facing a securities fraud investigation following the unexpected resignation of its auditor, CohnReznick LLP. This event has led to a significant decline in the company's stock price, dropping more than 20% shortly after the announcement. In light of the investigation, Bleichmar Fonti & Auld LLP is encouraging impacted investors to seek additional information. The firm specializes in representing plaintiffs in securities class actions and is offering contingent legal services for affected stakeholders.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics' stock price dropped over 20% following the unexpected resignation of its auditor.
  • The company is under investigation for potential violations of federal securities laws.
  • Investors have been alerted to a securities fraud investigation.

Full Press Release Details

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

Why is ADMA Biologics under investigation?

ADMA Biologics is being investigated for possible violations of federal securities laws.

What caused the stock drop of ADMA Biologics?

The unexpected resignation of their auditor, CohnReznick LLP, led to a stock decline.

How much did ADMA's stock drop on October 10?

The stock price fell by over 20% during trading on October 10, 2024.

What does Bleichmar Fonti & Auld LLP offer for investors?

The firm offers legal options with no cost to ADMA investors, working on a contingency basis.

What is Bleichmar Fonti & Auld LLP's reputation?

The firm is recognized for its success in securities litigation, ranking among the top law firms.

Last updated: Oct 19, 2024